TGNA:FRA
Transgene SA
€0.66
arrow_downward
-0.91%(-0.0060) 1D
Oct 20, 8:05:56 AM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TGNA...
Open
€0.66
High
€0.66
Low
€0.66
Mkt. cap
188.86M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.48
52-wk low
€0.60
EPS
-€0.17
No. of employees
152
Open
€0.66
High
€0.66
Low
€0.66
Mkt. cap
188.86M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.48
52-wk low
€0.60
EPS
-€0.17
No. of employees
152
News stories
From web sources and news partners
TradingView
·
1 hour ago
The Dow Jones Index Opens 0.43% Higher
Breakingthenews.net
·
31 minutes ago
Dow up 400 points as earnings season heats up
PR Newswire
·
53 minutes ago
Chips Bounced, Builders Sank and Crude Sent Mixed Signals Heading Into Tuesday
Yahoo Finance
·
1 hour ago
DOW Gains on Projects & Self-Help Actions Amid Demand and Cost Woes
Profile
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
About Transgene SA